Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease.

However, a numerical trend for improvement was seen in the low-dose group compared to placebo. 3.4 Additional efficacy end points No statistically significant treatment effects were detected between active treatment and placebo for COWAT, CFT, CSDD, CFQ ( Supplementary Table 1 ), or the CGI-C ( Supplementary Table 2 ). 3.5 Pharmacokinetics ORM-12741 did not accumulate during the 12 weeks of treatment.

also in 1,012 other papers

The low dose showed an overall trend for improving Working Memory over the 12 weeks of treatment ( Fig. 2 ).

also in 4,871 other papers